Bridging Biomarker Breakthroughs to Bedsides (B4) Tour
October 14 @ 11:00 am - 5:00 pm
Join Discovery Life Sciences on October 14 in South San Francisco for Bridging Biomarker Breakthroughs to Bedsides, the final stop of our 2026 B4 Tour. Kevin Lin, VP & Head of Translational Medicine at Revolution Medicines, will explore the translational biomarker strategy behind RAS(ON) therapies, alongside leaders from Lunit, Incyte, Prism AI Therapeutics, and Mindpeak.
Free to attend, the event includes lunch, insightful discussions, and a cocktail reception with networking among Bay Area pharma, biotech, and translational medicine leaders.
Hosted by:
